Nanomedicine to Overcome Current Parkinson's Treatment Liabilities: A Systematic Review

Overview

Journal Neurotox Res

Publisher Springer

Specialty Neurology

Date 2016 Sep 2

PMID 27581037

Citations 8

Authors

Gabriel Henrique Hawthorne

Marcelo Picinin Bernuci

Mariza Bortolanza

Vitor Tumas

Ana Carolina Issy

Elaine Del-Bel

Affiliations

Soon will be listed here.

Abstract

Nanoparticles might be produced and manipulated to present a large spectrum of properties. The physicochemical features of the engineered nanomaterials confer to them different features, including the ability to cross the blood-brain barrier. The main objective of this review is to present the state-of-art research in nano manipulation concerning Parkinson's disease (PD). In the past few years, the association of drugs with nanoparticles solidly improved treatment outcomes. We systematically reviewed 28 studies, describing their potential contributions regarding the role of nanomedicine to increase the efficacy of known pharmacological strategies for PD treatment. Data from animal models resulted in the (i) improvement of pharmacological properties, (ii) more stable drug concentrations, (iii) longer half-live and (iv) attenuation of pharmacological adverse effects. As this approach is recent, with many of the described works being published less than 5 years ago, the expectancy is that this knowledge gives support to an improvement in the current clinical methods to the management of PD and other neurodegenerative diseases.

Citing Articles

Trends on Novel Targets and Nanotechnology-Based Drug Delivery System in the Treatment of Parkinson's disease: Recent Advancement in Drug Development.

Majumdar M, Badwaik H Curr Drug Targets. 2024; 25(15):987-1011.

PMID: 39313872 DOI: 10.2174/0113894501312703240826070530.

Lipidic Nanoparticles, Extracellular Vesicles and Hybrid Platforms as Advanced Medicinal Products: Future Therapeutic Prospects for Neurodegenerative Diseases.

Tsakiri M, Tsichlis I, Zivko C, Demetzos C, Mahairaki V Pharmaceutics. 2024; 16(3).

PMID: 38543244 PMC: 10975844. DOI: 10.3390/pharmaceutics16030350.

The Management of Parkinson's Disease: An Overview of the Current Advancements in Drug Delivery Systems.

Nakmode D, Day C, Song Y, Garg S Pharmaceutics. 2023; 15(5).

PMID: 37242745 PMC: 10223383. DOI: 10.3390/pharmaceutics15051503.

Investigating the Targeting Power to Brain Tissues of Intranasal Rasagiline Mesylate-Loaded Transferosomal In Situ Gel for Efficient Treatment of Parkinson's Disease.

ElShagea H, Makar R, Salama A, Elkasabgy N, Basalious E Pharmaceutics. 2023; 15(2).

PMID: 36839855 PMC: 9967009. DOI: 10.3390/pharmaceutics15020533.

Nanogels as Novel Nanocarrier Systems for Efficient Delivery of CNS Therapeutics.

Zhang Y, Zou Z, Liu S, Miao S, Liu H Front Bioeng Biotechnol. 2022; 10:954470.

PMID: 35928954 PMC: 9343834. DOI: 10.3389/fbioe.2022.954470.

References

Scognamiglio V . Nanotechnology in glucose monitoring: advances and challenges in the last 10 years. Biosens Bioelectron. 2013; 47:12-25. DOI: 10.1016/j.bios.2013.02.043. View

Marconi S, Zwingers T . Comparative efficacy of selegiline versus rasagiline in the treatment of early Parkinson's disease. Eur Rev Med Pharmacol Sci. 2014; 18(13):1879-82. View

Xu Y, Deng Y, Qing H . The phosphorylation of α-synuclein: development and implication for the mechanism and therapy of the Parkinson's disease. J Neurochem. 2015; 135(1):4-18. DOI: 10.1111/jnc.13234. View

Ruiz-DeDiego I, Naranjo J, Herve D, Moratalla R . Dopaminergic regulation of olfactory type G-protein α subunit expression in the striatum. Mov Disord. 2015; 30(8):1039-49. DOI: 10.1002/mds.26197. View

Park S, Song H, Kwon O, Chung J, Lee S, An J . Human dopamine receptor nanovesicles for gate-potential modulators in high-performance field-effect transistor biosensors. Sci Rep. 2014; 4:4342. PMC: 3949245. DOI: 10.1038/srep04342. View

Demirel M, Yazan Y, Muller R, Kilic F, Bozan B . Formulation and in vitro-in vivo evaluation of piribedil solid lipid micro- and nanoparticles. J Microencapsul. 2001; 18(3):359-71. DOI: 10.1080/02652040010018119. View

Ruiz-DeDiego I, Mellstrom B, Vallejo M, Naranjo J, Moratalla R . Activation of DREAM (downstream regulatory element antagonistic modulator), a calcium-binding protein, reduces L-DOPA-induced dyskinesias in mice. Biol Psychiatry. 2014; 77(2):95-105. DOI: 10.1016/j.biopsych.2014.03.023. View

Sharma S, Lohan S, Murthy R . Formulation and characterization of intranasal mucoadhesive nanoparticulates and thermo-reversible gel of levodopa for brain delivery. Drug Dev Ind Pharm. 2013; 40(7):869-78. DOI: 10.3109/03639045.2013.789051. View

Yue K, Guduru R, Hong J, Liang P, Nair M, Khizroev S . Magneto-electric nano-particles for non-invasive brain stimulation. PLoS One. 2012; 7(9):e44040. PMC: 3434207. DOI: 10.1371/journal.pone.0044040. View

10.

De Giglio E, Trapani A, Cafagna D, Sabbatini L, Cometa S . Dopamine-loaded chitosan nanoparticles: formulation and analytical characterization. Anal Bioanal Chem. 2011; 400(7):1997-2002. DOI: 10.1007/s00216-011-4962-y. View

11.

Joshi N, Basak S, Kundu S, De G, Mukhopadhyay A, Chattopadhyay K . Attenuation of the early events of α-synuclein aggregation: a fluorescence correlation spectroscopy and laser scanning microscopy study in the presence of surface-coated Fe3O4 nanoparticles. Langmuir. 2015; 31(4):1469-78. DOI: 10.1021/la503749e. View

12.

Hamidi M, Azadi A, Rafiei P, Ashrafi H . A pharmacokinetic overview of nanotechnology-based drug delivery systems: an ADME-oriented approach. Crit Rev Ther Drug Carrier Syst. 2013; 30(5):435-67. DOI: 10.1615/critrevtherdrugcarriersyst.2013007419. View

13.

Yang X, Zheng R, Cai Y, Liao M, Yuan W, Liu Z . Controlled-release levodopa methyl ester/benserazide-loaded nanoparticles ameliorate levodopa-induced dyskinesia in rats. Int J Nanomedicine. 2012; 7:2077-86. PMC: 3356186. DOI: 10.2147/IJN.S30463. View

14.

Mercante L, Pavinatto A, Iwaki L, Scagion V, Zucolotto V, Oliveira Jr O . Electrospun polyamide 6/poly(allylamine hydrochloride) nanofibers functionalized with carbon nanotubes for electrochemical detection of dopamine. ACS Appl Mater Interfaces. 2015; 7(8):4784-90. DOI: 10.1021/am508709c. View

15.

Lindner G, Santos D, Colle D, Moreira E, Prediger R, Farina M . Improved neuroprotective effects of resveratrol-loaded polysorbate 80-coated poly(lactide) nanoparticles in MPTP-induced Parkinsonism. Nanomedicine (Lond). 2015; 10(7):1127-38. DOI: 10.2217/nnm.14.165. View

16.

Pathak K, Akhtar N . Nose to Brain Delivery of Nanoformulations for Neurotherapeutics in Parkinson`s disease: Defining the Preclinical, Clinical and toxicity issues. Curr Drug Deliv. 2016; . View

17.

So R, McConnell G, August A, Grill W . Characterizing effects of subthalamic nucleus deep brain stimulation on methamphetamine-induced circling behavior in hemi-Parkinsonian rats. IEEE Trans Neural Syst Rehabil Eng. 2012; 20(5):626-35. PMC: 3699208. DOI: 10.1109/TNSRE.2012.2197761. View

18.

Hasadsri L, Kreuter J, Hattori H, Iwasaki T, George J . Functional protein delivery into neurons using polymeric nanoparticles. J Biol Chem. 2009; 284(11):6972-81. PMC: 2652328. DOI: 10.1074/jbc.M805956200. View

19.

Padovan-Neto F, Ferreira N, de Oliveira-Tavares D, de Aguiar D, da Silva C, Raisman-Vozari R . Anti-dyskinetic effect of the neuronal nitric oxide synthase inhibitor is linked to decrease of FosB/deltaFosB expression. Neurosci Lett. 2013; 541:126-31. DOI: 10.1016/j.neulet.2013.02.015. View

20.

Agarwal S, Mishra P, Shivange G, Kodipelli N, Moros M, de la Fuente J . Citrate-capped gold nanoparticles for the label-free detection of ubiquitin C-terminal hydrolase-1. Analyst. 2014; 140(4):1166-73. DOI: 10.1039/c4an01935k. View